Literature DB >> 33651343

Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.

Athanasios D Anastasilakis1, Stergios A Polyzos2, Maria P Yavropoulou3, Charikleia Ntenti2, Stylianos Mandanas4, Polyzois Makras5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33651343     DOI： 10.1007/s12020-021-02666-5

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  8 in total

Review 1.  Certainties and Uncertainties About Denosumab Discontinuation.

Authors:  Elena Tsourdi; M Carola Zillikens
Journal:  Calcif Tissue Int       Date:  2018-06-15       Impact factor: 4.333

2.  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.

Authors:  A D Anastasilakis; S A Polyzos; A Gkiomisi; Z G Saridakis; D Digkas; I Bisbinas; G T Sakellariou; A Papatheodorou; P Kokkoris; P Makras
Journal:  Osteoporos Int       Date:  2015-05-20       Impact factor: 4.507

3.  Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.

Authors:  A Fassio; G Adami; C Benini; E Vantaggiato; K G Saag; A Giollo; I Lippolis; O Viapiana; L Idolazzi; G Orsolini; M Rossini; D Gatti
Journal:  Bone       Date:  2019-03-22       Impact factor: 4.398

4.  Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.

Authors:  Davide Gatti; Ombretta Viapiana; Luca Idolazzi; Elena Fracassi; Claudio Ionescu; Carmela Dartizio; Sonila Troplini; Vidya Kunnathully; Silvano Adami; Maurizio Rossini
Journal:  Bone       Date:  2014-07-05       Impact factor: 4.398

5.  Teriparatide and denosumab combination therapy and skeletal metabolism.

Authors:  L Idolazzi; M Rossini; O Viapiana; V Braga; A Fassio; C Benini; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-06-01       Impact factor: 4.507

Review 6.  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Polyzois Makras
Journal:  Eur J Endocrinol       Date:  2018-04-24       Impact factor: 6.664

7.  Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

Authors:  Elena Tsourdi; Polyzois Makras; Tilman D Rachner; Stergios Polyzos; Martina Rauner; Stylianos Mandanas; Lorenz C Hofbauer; Athanasios D Anastasilakis
Journal:  Bone       Date:  2018-10-04       Impact factor: 4.398

8.  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Athina Gkiomisi; Ilias Bisbinas; Spyridon Gerou; Polyzois Makras
Journal:  J Clin Endocrinol Metab       Date:  2013-06-20       Impact factor: 5.958
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.